<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:yt="http://gdata.youtube.com/schemas/2007" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
   <channel>
      <title>Drug Discovery Blogs Feed</title>
      <description>Pipes Output</description>
      <link>http://pipes.yahoo.com/pipes/pipe.info?_id=aa5393e3448ec37a8fd268ae7e4a034c</link>
      <atom:link rel="next" href="http://pipes.yahoo.com/pipes/pipe.run?_id=aa5393e3448ec37a8fd268ae7e4a034c&amp;_render=rss&amp;page=2" />
      <pubDate>Sun, 27 May 2012 17:55:12 +0000</pubDate>
      <generator>http://pipes.yahoo.com/pipes/</generator>
      <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/DrugDiscoveryBlogs" /><feedburner:info uri="drugdiscoveryblogs" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><feedburner:emailServiceId>DrugDiscoveryBlogs</feedburner:emailServiceId><feedburner:feedburnerHostname>http://feedburner.google.com</feedburner:feedburnerHostname><item>
         <title>Update on advanced prostate cancer including enzalutamide (MDV3100) and abiraterone</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/zS8DOCS6kbE/</link>
         <description>This month has brought a flurry of regulatory activity in the prostate cancer landscape with several companies seeing noticeable action in the new product development area: Medivation/Astellas filed enzalutamide (MDV3100) with the FDA in metastatic castration resistant prostate cancer (mCRPC) &amp;#8230; &lt;a rel="nofollow" target="_blank" href="http://pharmastrategyblog.com/2012/05/update-on-advanced-prostate-cancer-including-enzalutamide-mdv3100-and-abiraterone.html/"&gt;Continue reading &lt;span class="meta-nav"&gt;&amp;#8594;&lt;/span&gt;&lt;/a&gt;&lt;p&gt;&lt;/p&gt;&lt;div class="feedflare"&gt;
&lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?a=8qHHUTrJoY4:3za3D_6ueIM:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?d=yIl2AUoC8zA" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?a=8qHHUTrJoY4:3za3D_6ueIM:gIN9vFwOqvQ"&gt;&lt;img src="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?i=8qHHUTrJoY4:3za3D_6ueIM:gIN9vFwOqvQ" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?a=8qHHUTrJoY4:3za3D_6ueIM:TzevzKxY174"&gt;&lt;img src="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?d=TzevzKxY174" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?a=8qHHUTrJoY4:3za3D_6ueIM:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?d=qj6IDK7rITs" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?a=8qHHUTrJoY4:3za3D_6ueIM:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?i=8qHHUTrJoY4:3za3D_6ueIM:F7zBnMyn0Lo" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?a=8qHHUTrJoY4:3za3D_6ueIM:c-S6u7MTCTE"&gt;&lt;img src="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?d=c-S6u7MTCTE" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?a=8qHHUTrJoY4:3za3D_6ueIM:-BTjWOF_DHI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/PharmaStrategyBlog?i=8qHHUTrJoY4:3za3D_6ueIM:-BTjWOF_DHI" border="0"&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/PharmaStrategyBlog/~4/8qHHUTrJoY4" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=zS8DOCS6kbE:3za3D_6ueIM:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=zS8DOCS6kbE:3za3D_6ueIM:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=zS8DOCS6kbE:3za3D_6ueIM:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=zS8DOCS6kbE:3za3D_6ueIM:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=zS8DOCS6kbE:3za3D_6ueIM:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=zS8DOCS6kbE:3za3D_6ueIM:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/zS8DOCS6kbE" height="1" width="1"/&gt;</description>
         <guid isPermaLink="false">http://pharmastrategyblog.com/?p=5271</guid>
         <pubDate>Fri, 25 May 2012 15:15:40 +0000</pubDate>
      <feedburner:origLink>http://feedproxy.google.com/~r/PharmaStrategyBlog/~3/8qHHUTrJoY4/</feedburner:origLink></item>
      <item>
         <title>Deals Of The Week Jump Starts The Summer Reading List</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/6ZLe5373oL0/deals-of-week-jump-starts-summer.html</link>
         <description>&lt;div class="separator" style="clear:both;text-align:center;"&gt;&lt;a rel="nofollow" target="_blank" href="http://1.bp.blogspot.com/-4z5UaTXiGL4/T7_QSEqRJ4I/AAAAAAAAER8/PRxILxcK1uI/s1600/4608849895_635bec26e5_z.jpg" style="margin-left:1em;margin-right:1em;"&gt;&lt;img border="0" height="300" src="http://1.bp.blogspot.com/-4z5UaTXiGL4/T7_QSEqRJ4I/AAAAAAAAER8/PRxILxcK1uI/s400/4608849895_635bec26e5_z.jpg" width="400"/&gt;&lt;/a&gt;&lt;/div&gt;High on the &lt;i&gt;New York Times&lt;/i&gt; List of Bestsellers (in the hardcover advice &amp;amp; miscellaneous category) this spring has been the book&lt;a rel="nofollow" target="_blank" href="http://query.nytimes.com/gst/fullpage.html?res=9502E6D6123EF935A35756C0A9649D8B63"&gt; “Innovation: Create Far From Home, Win Everywhere.”&lt;/a&gt;&lt;br /&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;It’s by two well-known Dartmouth business school professors, Vijay Govindarajan and Chris Trimble, and tracks how innovation originating in emerging markets is finding its way into the broader global business world. Since the topic’s increasingly relevant to pharma – although the book isn’t specific to healthcare -- and since the book arrived on my desk this morning, I’m giving it priority status for my Memorial Day weekend reading. Besides, it ties in nicely with one of the themes on my mind since attending the &lt;a rel="nofollow" target="_blank" href="http://www.bionj.org/events/usa-india-biopharma-healthcare-summit"&gt;US-India Chamber Of Commerce Healthcare Summit&lt;/a&gt; on May 11 in Cambridge, MA. &lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;That meeting &lt;i&gt;was &lt;/i&gt;focused on biopharma, and started with a talk by Elias Zerhouni, president of Sanofi's Global R&amp;amp;D, on innovation and India. Billed as the keynote, he had to cancel plans to attend at the last minute and instead participated from Paris, via a near-lifelike videocast.&amp;nbsp; “I was struck several years ago by the extraordinary ability of the healthcare system in India to adopt new technologies to provide high quality care at low cost…so I know there is the fundamental power and energy to create in India,” he started off. &lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;S&lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/Publications/Pharmasia-News/2011/5/26/Is-Sanofi-Planning-HighLevel-Changes-At-Indias-Vaccines-Unit-Shantha-A-Leading-Biocon-Scientist-Joins?result=20&amp;amp;total=98&amp;amp;searchquery=%253fq%253dshantha%2526start%253d11"&gt;anofi, of course, bought India’s Shantha Biotechnics vaccines business&lt;/a&gt;, where it is working to produce vaccines at low cost for the global market.&amp;nbsp; The &lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/Publications/The-Pink-Sheet-Daily/2011/5/16/Sanofi-Continues-Search-For-Novel-Compounds-In-Asia-Inking-Deal-With-Indias-Glenmark-For-Phase-I-Biologic?result=21&amp;amp;total=70&amp;amp;searchquery=%253fq%253d%252522sanofi%252522%252520and%252520%252522Glenmark%252522%2526start%253d21"&gt;company also has a partnership with Glenmark&lt;/a&gt; on developing a monoclonal antibody for inflammatory diseases. “It is possible to see that India has capability of addressing very fundamental obstacles that exist in R&amp;amp;D,” Zerhouni said. "…No one, no country, no organization, has all the needs to master the complexity of biology and to have access patient population and patient samples that would give us profound insights into disease. The role of India is to innovate, not just the delivery of health care, which it has been excellent at doing, not just be less costly, what makes the difference is creativity.”&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;Zerhouni wasn’t specific but others at the one-day conference gave examples. The Boston Consulting Group has studied India’s capacity for innovation in healthcare, which BCG partner Bart Janssens, who is based in Mumbai, called India’s “magic beans.” According to BCG, these are information technology and computational research, which could help direct pharma’s growing appetite for big datasets (biology is becoming an information science, one speaker noted). Also on the list: nanotechnology and, to no one’s surprise, process efficiencies, a hot topic, particularly in the area of translational research .&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;And much of the discussion centered around innovative approaches to clinical trials, &lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/Publications/Pharmasia-News/2012/5/21/Is-India-Falling-Behind-Its-Neighbors-In-Attracting-Clinical-Research?result=1&amp;amp;total=1&amp;amp;searchquery=%253fq%253d%252522john%252520Leonard%252522%2526source%253dPharmAsia%252520News"&gt;where India and U.S. academic institutions and MNCs are working aggressively&lt;/a&gt; on projects that are sure to change the nature of the way clinical trials are done globally -- but may not be moving fast enough, as colleague Josh Berlin points out in his excellent take on the summit.&amp;nbsp; &lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;In health care, much of the reverse innovation activity has been on the device side, which Govindarajan and Trimble, along with GE CEO Jeff Immelt, wrote about in the Harvard Business Review in October 2009. That article received a lot of attention and gave some circles in pharma food for thought, although pharma seems to be a step behind.&lt;br /&gt;&lt;br /&gt;Nevertheless, as I grab the book and run out the door, with more say on this post-holiday, it seems worth pointing out a mainstay of pharma's efforts to capture innovation, namely through deal making. And this week's activities boil down to....&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&amp;nbsp; &lt;/div&gt;&lt;div class="separator" style="clear:both;text-align:center;"&gt;&lt;a rel="nofollow" target="_blank" href="http://1.bp.blogspot.com/-K5jXQuPcF64/T7-QcFSOIgI/AAAAAAAAAIg/KKkKhQkVFvY/s1600/DOTWlogo.jpg" style="margin-left:1em;margin-right:1em;"&gt;&lt;img border="0" height="22" src="http://1.bp.blogspot.com/-K5jXQuPcF64/T7-QcFSOIgI/AAAAAAAAAIg/KKkKhQkVFvY/s320/DOTWlogo.jpg" width="320"/&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&amp;nbsp; &lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;b style=""&gt;IMI/GSK/AZ/Sanofi/Basilea/Janssen Pharmaceuticals:&lt;/b&gt; In an effort to address concerns about the increasing resistance of bacteria to the currently available antibiotics, a European initiative launched in November announced &lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/publications/the-pink-sheet-daily/2012/5/24/the-atlantic-divides-thinking-on-antibiotic-issue-solutions"&gt;May 24 that it is forming a public-private collaboration coined NewDrugs4BadBugs to fund the development of new antibiotics&lt;/a&gt;. The &lt;a rel="nofollow" target="_blank" href="http://www.imi.europa.eu/sites/default/files/uploads/documents/Press%20Releases/IMIpressRelease6thCallFINAL.pdf"&gt;Innovative Medicines Initiative, part of the EuropeanCommission’s Action Plan against the Rising Threat From Antimicrobial Resistance, is providing €119 million&lt;/a&gt; ($149.6 million) in funding. Private companies – GlaxoSmithKline, Sanofi, AstraZeneca, Janssen, and Basilea – will contribute a combined €114.7 million ($144.1 million). Perhaps more important, however, is the companies’ commitment to share data. &amp;nbsp;The group is forming a committee, which will build a website that can facilitate the sharing of this information, including specifics on failed targets and clinical trial data. The focus of the overall program will be to develop better networks of researchers, create more fluid trial designs, and provide incentives for companies to participate. The collaboration in the EU happens to parallel proposed legislation in the U.S. that is meant to increase the exclusivity period for antibiotics developed to combat certain types of multi-drug resistant bacteria. Both the U.S. and EU are trying to increase the number of antibiotics under development as more and more people continue to die from infections that were not previously fatal. &lt;i style=""&gt;--Lisa LaMotta&lt;/i&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;b style=""&gt;Labcorp/XDx:&lt;/b&gt;&amp;nbsp; With Labcorp., molecular diagnostics developer XDx has found a partner to enable it to resume development of a diagnostic to predict when lupus flares may occur. Lupus has always been in XDx’s sights.&amp;nbsp; But its early discovery efforts were not sufficient to winnow down potential candidate markers to a set ripe for clinical validation. It also had tabled a clinical study in 2010, &lt;a rel="nofollow" target="_blank" href="http://www.clinicaltrials.gov/ct2/show/NCT00671047?term=xdx&amp;amp;rank=2"&gt;SAGE&lt;/a&gt;,  600 patients short of its original goal of 1000, because it had to direct resources toward its lead product, the heart transplant diagnostic, AlloMap.&amp;nbsp;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;However, through SAGE, XDx obtained an exotic lupus-oriented set of samples: blood and information on clinical parameters collected monthly from patients. “We knew a certain percentage of these patients would have a significant flare event,” says COO Mitchell Nelles. By drawing blood monthly, the company would have samples before and after flare events, allowing XDx to look for biomarker signatures which could then be used to predict those flares. Now, Labcorp has shown interest in this diagnostics discovery approach. &lt;a rel="nofollow" target="_blank" href="http://www.xdx.com/documents/2012%20Press%20Release/Develop_Lupus_Flare_Test.pdf"&gt;In a deal announced May 23&lt;/a&gt;,&lt;span style="background:none repeat scroll 0% 0% yellow;"&gt;&lt;/span&gt; the companies are collaborating to develop a test to predict lupus flares, to which Labcorp will have full US commercial rights.&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;A flare predictor test could potentially tell a physician when to intervene with a drug.&amp;nbsp; Even more important, if it were to have a high negative predictive value, the test could tell a physician when to reduce the use of steroids and minimize side effects or generally adjust downward the level of medication.&amp;nbsp; The aim would be “not just preventing the flare, it’s not having to give more medicine than a patient needs,” Nelles says.&amp;nbsp; “We’ve seen that in the transplant field and also autoimmunity. The opportunities to reduce medication to the lowest level possible can have a profound clinical impact.” The test would likely contain a combination of gene expression and protein biomarkers. XDx retains the right to work with other potential pharma/biotech partners to develop a companion diagnostic to predict drug response and otherwise manage therapy.&amp;nbsp; It had previously worked with Bristol-Myers as part of BMS’s clinical plan to develop its arthritis drug Orencia in lupus, an effort which ultimately failed due to the drug's lack of efficacy in Phase III. &lt;i style=""&gt;– Mark Ratner&lt;/i&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;b style=""&gt;GSK/Auxilium: &lt;/b&gt;&lt;a rel="nofollow" target="_blank" href="http://www.marketwatch.com/story/auxilium-pharmaceuticals-inc-and-glaxosmithkline-llc-enter-into-a-co-promotion-agreement-for-testim-in-the-us-2012-05-21?reflink=MW_news_stmp"&gt;GlaxoSmithKline and Auxilium Pharmaceuticals announced May 21 that they have teamed up&lt;/a&gt; on the marketing of the Malvern, Pa-based biotech’s testosterone gel, &lt;i&gt;Testim&lt;/i&gt;. The co-promotion agreement is set to begin early in the third quarter and is slated to last until September 2015. That's when generics start to infiltrate the $1.4 billion testosterone gel market, which is currently all branded. In the meantime, this promotion will help Auxilium maximize its product before competition arrives. The British pharma will be responsible for increasing awareness of U.S. physicians, while Auxilium will still manufacture the product. GSK will receive revenues on the drug if it exceeds an undisclosed baseline sales figure. Testim, which is meant to treat conditions related to low testosterone levels, generated sales of $208 million in 2011 and accounted for about 80% of Auxilium’s revenues. Just a day after announcing the deal, Auxilium filed suit against Watson Pharmaceuticals in the U.S. District Court of N.J. claiming the generic drug maker’s plan to launch a generic of Testim is in violation of several patents. Other testosterone gel manufacturers like Par Pharmaceuticals and Abbott have reached agreements with Watson to keep a low-cost generic off the market until at least August 2015 – it appears Auxilium is trying to get the most out of its branded product before the compe&lt;a rel="nofollow" target="_blank" href="http://www.blogger.com/blogger.g?blogID=36634196" name="_GoBack"&gt;t&lt;/a&gt;ition arrives. --&lt;i style=""&gt;LL&lt;/i&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;b style=""&gt;DaVita Inc./HealthCare Partners:&amp;nbsp; &lt;/b&gt;DaVita, which manages more than 1,800 dialysis centers across the U.S serving 145,000 patients, is &lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/Publications/The-Pink-Sheet-Daily/2012/5/21/DaVita-Shifts-Its-Business-Model-With-HealthCare-Partners-Acquisition?result=1&amp;amp;total=11&amp;amp;searchquery=%253fq%253ddavita%2526source%253dThe%252520Pink%252520Sheet%252520DAILY"&gt;buying one of California’s largest independent physician associations, HealthCare Partners, for $4.4 billion&lt;/a&gt;. HCP generated $2.4 billion in revenues in 2011 from services its 700 physicians provide to 667,000 people in Southern California, Central Florida and Nevada. The deal is valued at about 8.4x HCP’s 2011 EBITDA. That’s big news in the provider services and dialysis worlds, but what does it mean for pharma?&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;Once integrated into DaVita, HCP will operate as a separate subsidiary and its current management will continue to run daily operations. DaVita isn’t likely to get much of a bump in its presence in the dialysis market. Rather, it sees the addition of HCP as a way to build on an integrated care approach, based on HCP’s ongoing efforts to work closely with payers and consumers. While the companies were not specific about how HCP interacts with the groups it services, they noted in the analysts’ call that in certain disease categories — chronic obstructive pulmonary disease, for example — more integrated care with physicians and patients working closely together resulted in shorter hospital stays and no increase in hospital readmissions. In addition, HCP collects claims and administrative data, which, combined with clinical data, allows it to develop clinical programs geared to specific patient populations.&amp;nbsp;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;This strategy, while not directly impacting pharma in the near-term, reflects a move on the part of providers and payers to seek what is increasingly known as “a continuum of care” for patients.&amp;nbsp; Pharmaceutical companies have generally taken a wait-and-see approach to such efforts, before responding with new product portfolios and commercial models that address the shifting needs of their constituents. But the trend is on their minds and some, particularly those involved in diabetes, such as &lt;b style=""&gt;Sanofi&lt;/b&gt;, are forging ahead with continuum of care strategies; &lt;b style=""&gt;Endo Health Solutions&lt;/b&gt;, which recently changed its name from &lt;b style=""&gt;Endo Pharmaceuticals&lt;/b&gt; to better reflect the diversity and focus of its pipeline, is taking a continuum of care approach to the urology and oncology sub-segments.&lt;i style=""&gt;—LL&lt;/i&gt; &lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;/div&gt;&amp;nbsp;  &lt;br /&gt;&lt;div class="21StorySub-Head" style="background-color:yellow;"&gt;&lt;b&gt;&lt;span style="font-weight:normal;"&gt;&lt;/span&gt;&lt;/b&gt; &lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;b&gt;Takeda/Multilab Industria&lt;/b&gt;: Japanese firm Takeda Pharmaceutical claims a leading position in Brazil’s pharmaceutical space with the May 25 purchase of Multilab Industria e Comercio de Produtos&lt;b&gt; Farmaceuticos&lt;/b&gt;, which manufactures branded generics and OTCs. The transaction, worth an upfront payment of BRL 500 million ($245.5 million), plus up to BRL 40 million, makes Osaka-based Takeda one of Brazil’s top 10 pharma players and brings it the country’s top-selling OTC cold and flu remedy, &lt;i&gt;Multigrip&lt;/i&gt;. Takeda expects to close the deal by September.&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;Through&lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/Publications/The-Tan-Sheet/19/21/Takeda-Gains-Access-To-European-OTC-Market-With-137B-Nycomed-Buy?result=1&amp;amp;total=1&amp;amp;searchquery=%253fq%253d05110523014"&gt; its 2011 acquisition of Swiss firm Nycomed&lt;/a&gt;, Takeda has an OTC presence in Brazil, including the analgesic brand &lt;i&gt;Neosaldina&lt;/i&gt;, and Rio Grande do Sul-based Multilab is expected to complement that business via its established distribution network, especially in emerging parts of Brazil. Takeda recently projected sales in Latin America, including Brazil, will reach JPY 52 billion&amp;nbsp; ($651.9 million) in 2012, and the firm does not plan to revise this year’s earnings guidance following the deal. Multilab generated revenue of about $68.8 million in 2011.--&lt;i style=""&gt;Dan Schiff&lt;/i&gt;&lt;span style="color:black;font-size:10pt;"&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;/div&gt;&lt;div class="21StorySub-Head"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;b style=""&gt;Valeant/Swiss Herbal Remedies Ltd.:&lt;/b&gt; Aggressive pharma acquirer Valeant Pharmaceuticals purchases assets from Canadian natural health product firm Swiss Herbal Remedies, the latest consumer health pickup for Montreal-based Valeant. In a May 24 release, Valeant said Swiss Herbal is well-known in Canada and will complement the &lt;i&gt;Cold-FX&lt;/i&gt; NHP brand Valeant acquired along with &lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/Publications/The-Tan-Sheet/19/36/Valeant-Deal-Would-Aid-Afexas-iColdFXi-Expansion-Plans?result=1&amp;amp;total=1&amp;amp;searchquery=%253fq%253d05110905007"&gt;Afexa Life Sciences in 2011&lt;/a&gt;. Valeant paid less than 1x sales for the assets from Richmond Hill, Ontario-based Swiss Herbal; the assets generated 2011 net revenue of CA $28 million (U.S. $27.4 million)&lt;i style=""&gt;.—DS&lt;/i&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;b style=""&gt;Suneva/Spear&lt;/b&gt;&lt;b&gt;:&lt;/b&gt;&amp;nbsp; Fallout from Valeant's hectic deal-making pace continued May 24 as the anti-wrinkle product &lt;i style=""&gt;Refissa&lt;/i&gt;(tretinoin 0.5%) moved to a new home for the second time in less than a year. In December 2011, following Valeant’s buyouts of Sanofi’s Dermik Laboratories and Janssen’s Ortho Dermatologics, the &lt;a rel="nofollow" target="_blank" href="http://www.elsevierbi.com/Publications/The-Pink-Sheet-Daily/2011/12/20/Valeants-Latest-MampA-Gambit-Hits-Snag-With-Istas-Rejection-Of-314-Million-Buyout-Offer?result=1&amp;amp;total=1&amp;amp;searchquery=%253fq%253d14111220004"&gt;Federal Trade Commission required the specialty pharma todivest three dermatology products from its portfolio&lt;/a&gt; – Refissa, acne medication &lt;i style=""&gt;BenzaClin &lt;/i&gt;and topical flurorouracil cream &lt;i style=""&gt;5FU&lt;/i&gt;. Valeant sold Refissa, indicated for fine facial lines, hyperpigmentation and tactile roughness, to Spear Pharmaceuticals, and the other two products to Mylan Pharmaceuticals. For undisclosed financial terms, Spear has sold worldwide rights to Refissa and a generic version developed and launched by Spear to privately held Suneva. Suneva CEO Nick Teti said his firm is entering the prescription topical aesthetic space, which he called a potential $100 million market opportunity. The addition will enable its marketing force to offer aesthetic physicians “a comprehensive anti-aging solution,” also include Suneva’s proprietary &lt;i style=""&gt;ReGenica&lt;/i&gt;skincare products and its injectable filler &lt;i style=""&gt;Artefill&lt;/i&gt;. Suneva called the deal transformational and said Refissa will be a key driver of sales growth over the next five years.—&lt;i style=""&gt;Joseph Haas&lt;/i&gt;&lt;a rel="nofollow" target="_blank" href="http://www.blogger.com/blogger.g?blogID=36634196" name="_GoBack"&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class="MsoNormal"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="22StoryText"&gt;&lt;i&gt;&lt;a rel="nofollow" target="_blank" href="http://www.flickr.com/photos/mysapl/4608849895/sizes/z/in/photostream/"&gt;image&lt;/a&gt; from flickr user mySAPL used under creative commons &lt;/i&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;© Copyright 2007-2011 Windhover Information Inc.
www.windhover.com/blog&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/36634196-5364876708971569981?l=invivoblog.blogspot.com' alt=''/&gt;&lt;/div&gt;&lt;div class="feedflare"&gt;
&lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/invivoblog?a=sWni2tTZeOI:yQwPWp98FPA:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/invivoblog?d=yIl2AUoC8zA" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/invivoblog?a=sWni2tTZeOI:yQwPWp98FPA:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/invivoblog?d=I9og5sOYxJI" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/invivoblog?a=sWni2tTZeOI:yQwPWp98FPA:bcOpcFrp8Mo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/invivoblog?d=bcOpcFrp8Mo" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/invivoblog?a=sWni2tTZeOI:yQwPWp98FPA:qj6IDK7rITs"&gt;&lt;img src="http://feeds.feedburner.com/~ff/invivoblog?d=qj6IDK7rITs" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/invivoblog?a=sWni2tTZeOI:yQwPWp98FPA:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/invivoblog?i=sWni2tTZeOI:yQwPWp98FPA:V_sGLiPBpWU" border="0"&gt;&lt;/a&gt; &lt;a rel="nofollow" target="_blank" href="http://feeds.feedburner.com/~ff/invivoblog?a=sWni2tTZeOI:yQwPWp98FPA:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/invivoblog?i=sWni2tTZeOI:yQwPWp98FPA:F7zBnMyn0Lo" border="0"&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/invivoblog/~4/sWni2tTZeOI" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=6ZLe5373oL0:yQwPWp98FPA:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=6ZLe5373oL0:yQwPWp98FPA:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=6ZLe5373oL0:yQwPWp98FPA:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=6ZLe5373oL0:yQwPWp98FPA:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=6ZLe5373oL0:yQwPWp98FPA:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=6ZLe5373oL0:yQwPWp98FPA:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/6ZLe5373oL0" height="1" width="1"/&gt;</description>
         <author>Wendy Diller</author>
         <guid isPermaLink="false">tag:blogger.com,1999:blog-36634196.post-5364876708971569981</guid>
         <pubDate>Fri, 25 May 2012 13:33:00 +0000</pubDate>
         <media:thumbnail height="72" url="http://1.bp.blogspot.com/-4z5UaTXiGL4/T7_QSEqRJ4I/AAAAAAAAER8/PRxILxcK1uI/s72-c/4608849895_635bec26e5_z.jpg" width="72" />
      <feedburner:origLink>http://feedproxy.google.com/~r/invivoblog/~3/sWni2tTZeOI/deals-of-week-jump-starts-summer.html</feedburner:origLink></item>
      <item>
         <title>A Toxic Tale Of Serendipity</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/wQMTDDWqRRc/</link>
         <description>This post is from guest blogger Lila Guterman, senior editor for C&amp;#38;EN&amp;#8217;s Journal News &amp;#38; Community group, and was written for the &amp;#8220;Our Favorite Toxic Chemicals&amp;#8221; blog carnival. I have long had a fondness for weird, complex, toxic natural products. (Witness three recent stories I assigned and edited.) So when ScienceGeist announced the “Our Favorite Toxic Chemicals” blog carnival, I [...]</description>
         <guid isPermaLink="false">http://8.2729</guid>
         <pubDate>Fri, 25 May 2012 13:29:44 +0000</pubDate>
         <content:encoded><![CDATA[<p><em>This post is from guest blogger <a rel="nofollow" target="_blank" href="http://cen.acs.org/static/about/staff_landing/biolg.html">Lila Guterman,</a> senior editor for C&amp;EN&#8217;s Journal News &amp; Community group, and was written for the &#8220;Our Favorite Toxic Chemicals&#8221; blog carnival.</em></p>
<p>I have long had a fondness for weird, complex, toxic natural products. (Witness <a rel="nofollow" target="_blank" href="http://cen.acs.org/articles/90/web/2012/03/Algal-Toxin-Breaks-Record.html">three</a> <a rel="nofollow" target="_blank" href="http://cen.acs.org/articles/89/web/2011/05/Hawaiian-Monk-Seals-Carry-Ciguatoxins.html">recent</a> <a rel="nofollow" target="_blank" href="http://cen.acs.org/articles/89/web/2011/08/Frog-Skin-Packs-Chemical-Punch.html">stories</a> I assigned and edited.) So when <a rel="nofollow" target="_blank" href="http://sciencegeist.net/">ScienceGeist</a> announced the <a rel="nofollow" target="_blank" href="http://sciencegeist.net/our-favorite-toxic-chemicals/">“Our Favorite Toxic Chemicals</a>” blog carnival, I knew I’d have to participate. It would give me the chance to tell the story of homobatrachotoxin.</p>
<p>The story begins in 1963, with a young NIH chemist, John W. Daly, taking a trip to Colombia at the request of his boss to investigate the chemistry of frog secretions. His discoveries would launch his career as a<br />
chemical ecologist and pharmacologist, and would spur an <a rel="nofollow" target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=batrachotoxin">outpouring of research</a> into the toxin he discovered, batrachotoxin.</p>
<p>He <a rel="nofollow" target="_blank" href="http://www.sciencemag.org/content/172/3987/995.abstract">published the chemical structure</a>, the biological effects, and a partial synthesis, in 1971. Batrachotoxin and its natural analogs, homobatrachotoxin and batrachotoxinin A, are among the most toxic natural substances known. Just 200 ng kill a mouse in 8 minutes; the lethal dose for people is thought to be around 100 µg.</p>
<p>Daly and colleagues found that batrachotoxin binds to sodium channels, opening them. Researchers now use batrachotoxin to study how these channels interact with anesthetics, anticonvulsants, and antiarrhythmia agents.</p>
<div id="attachment_2738" class="wp-caption alignright" style="width:310px;"><a rel="nofollow" target="_blank" href="http://cenblog.org/newscripts/files/2012/05/yellow-frog2.jpg" class="thickbox no_icon" title=""><img class="size-medium wp-image-2738" src="http://cenblog.org/newscripts/files/2012/05/yellow-frog2-300x221.jpg" alt="" width="300" height="221"/></a><p class="wp-caption-text">Phyllobates terribilis. Credit: Micha Rieser</p></div>
<p>These alkaloid toxins are secreted by certain species of Colombian <a rel="nofollow" target="_blank" href="http://nationalzoo.si.edu/Animals/Amazonia/Facts/fact-poisondartfrog.cfm">poison-dart frogs</a> – so called because Indians in Western Colombia used their secretions to poison the tips of blow darts. The most poisonous frog, the bright yellow <em>Phyllobates terribilis, </em>secretes batrachotoxin at levels high enough to kill several people.</p>
<p>Daly developed an unorthodox method for deciding whether to collect a frog in the wild – one he was lucky, or prudent, enough not to try on <em>Phyllobates terribilis</em>: “It involved touching the frog, then sampling it on the tongue. If you got a burning sensation, then you knew this was a frog you ought to collect,” he <a rel="nofollow" target="_blank" href="http://nihrecord.od.nih.gov/newsletters/09_03_2002/story01.htm">told the <em>NIH Record</em></a>, in 2002. In his work with South and Central American frogs, Daly and his collaborators ended up isolating more than 500 new natural products.<span id="more-10355"></span></p>
<p>A series of chance occurrences led Daly to perhaps the most intriguing discovery of his career: that homobatrachotoxin is also secreted by a songbird that lives halfway around the world.</p>
<div id="attachment_2739" class="wp-caption alignleft" style="width:310px;"><a rel="nofollow" target="_blank" href="http://cenblog.org/newscripts/files/2012/05/homobatrachotoxin.gif" class="thickbox no_icon" title=""><img class="size-medium wp-image-2739" src="http://cenblog.org/newscripts/files/2012/05/homobatrachotoxin-300x105.gif" alt="" width="300" height="105"/></a><p class="wp-caption-text">The New Guinea songbirds Pitohui dichrous (left) and Ifrita kowaldi contain batrachotoxin alkaloids such as homobatrachotoxin, previously found only in poison-dart frogs. Credit: Photos by John Dumbacher</p></div>
<p>In 1989, <a rel="nofollow" target="_blank" href="http://research.calacademy.org/om/staff/jdumbacher">John P. Dumbacher</a>, then a graduate student in ornithology, was studying birds of paradise in New Guinea. His nets sometimes caught other birds, including a songbird called the hooded pitohui (<em>Pitohui dichrous</em>).</p>
<p>“These are large birds that can cut your hands, and as I struggled to free them, they bit and scratched my hands,” he <a rel="nofollow" target="_blank" href="http://www.cosmosmagazine.com/factfile/5123/hooded-pitohui-toxic-songbird">told COSMOS Magazine</a> this year. “These little scratches really stung, so I just put my fingers in my mouth to clean the cut, and after a minute or so my lips and tongue began to tingle and burn.”</p>
<p>Dumbacher once described the feeling in <a rel="nofollow" target="_blank" href="http://pubs.acs.org/isubscribe/journals/cen/78/i44/html/7844notw3.html">the pages of C&amp;EN</a> as “a lot like tasting hot chili peppers or touching a 9-volt battery.”</p>
<p>Dumbacher had trouble finding a chemist who would take seriously the idea that a bird could be poisonous. (He’d originally been skeptical, too: It took a second trip to New Guinea, in 1990, to convince himself that the birds were secreting toxins, he <a rel="nofollow" target="_blank" href="http://nationalzoo.si.edu/Publications/ZooGoer/2001/2/intoxnewguineabirds.cfm">told <em>Smithsonian ZooGoer</em></a>.) Only Daly agreed to look at the secretions, and he immediately recognized the mass spectrum of a batrachotoxin.</p>
<p>In 1992, Dumbacher, Daly, and colleagues <a rel="nofollow" target="_blank" href="http://www.sciencemag.org/content/258/5083/799.abstract">published their discovery</a> in <em>Science</em>: homobatrachotoxin in the skin and feathers of three species in the genus <em>Pitohui</em>. The levels of the toxin were far lower than in the frogs, but its presence was still startling: How could these two unrelated animals, separated by oceans and thousands of miles, both secrete a single complex steroidal toxin?</p>
<p>It was also the first paper to report a toxic substance from a bird.</p>
<p>“People were stunned by that first report,” Paul J. Weldon, of the Smithsonian Institution, <a rel="nofollow" target="_blank" href="http://pubs.acs.org/isubscribe/journals/cen/78/i44/html/7844notw3.html">told C&amp;EN in 2000</a>. “It floored the heck out of me.”</p>
<p>In 2000, the two researchers, with colleague Thomas F. Spande, reported the presence of <a rel="nofollow" target="_blank" href="http://www.pnas.org/content/97/24/12970">homobatrachotoxin<br />
in another bird</a> in New Guinea. This time it was the blue-capped  ifrita, from a different genus. Their finding raised the question: Do birds engage in chemical defense more commonly than scientists had realized?</p>
<p>Daly and Dumbacher also wanted to know where this outrageous organic compound came from. They realized the frogs and birds must both eat something that carried the toxin.</p>
<p><a rel="nofollow" target="_blank" href="http://pubs.acs.org/isubscribe/journals/cen/82/i45/html/8245notw8.html">A hint came in 2004</a>: After more than a decade of studying the pitohui diet, they finally found a group of <a rel="nofollow" target="_blank" href="http://www.pnas.org/content/101/45/15857.full">beetles in the genus <em>Choresine</em> that carry batrachotoxin</a> – and at high concentrations. (They found them thanks to a tingling sensation that local villagers reported from contact with the beetles.) The researchers think that the poison-dart frogs must eat relatives of the <em>Choresine</em> beetles that live in Colombia, though they have yet to discover them. Field research in that country has become far more difficult, due to its long-lasting civil war.</p>
<p>Still more questions remain unanswered: How did the birds and frogs evolve to sequester the highly potent alkaloid poison and to avoid its toxic effects? How do the beetles synthesize the toxin? Or do they eat something else that in turn made the batrachotoxin?</p>
<p>Dumbacher, who is now an ornithologist with the California Academy of Sciences, <a rel="nofollow" target="_blank" href="http://research.calacademy.org/sites/research.calacademy.org/files/Dumbacher%20Auk%202009.pdf">continues</a> to <a rel="nofollow" target="_blank" href="http://www.sciencedirect.com/science/article/pii/S1055790308004703">study</a> these questions.</p>
<p>But Daly’s work is done. He <a rel="nofollow" target="_blank" href="http://nihrecord.od.nih.gov/newsletters/2008/05_30_2008/story5.htm">died in 2008</a>. (NIH hosted and videotaped <a rel="nofollow" target="_blank" href="http://videocast.nih.gov/summary.asp?Live=6829">a tribute</a> to his life and prodigious career. The <em>Journal of Natural Products</em> also published <a rel="nofollow" target="_blank" href="http://pubs.acs.org/toc/jnprdf/73/3">a special issue</a> in his and another deceased scientist’s honor.)</p>
<p>Postscript:</p>
<p>ScienceGeist asked carnival participants to “talk about a toxic chemical that plays some nontoxic role in their lives.” This one doesn’t play a nontoxic role for me – apart from being the story that got away.</p>
<p>I first learned of the story behind the batrachotoxins in 2000 – it may even have been from the C&amp;EN story I’ve already linked a few times.</p>
<p>I was fascinated. I immediately called John Daly and interviewed him about the work. But at the time, I couldn’t find a way to wrangle it into a story that would work for the weekly publication where I was a science reporter. I’ve wanted to write about it for years but never found a way. I’m glad that C&amp;EN <a rel="nofollow" target="_blank" href="http://pubs.acs.org/cen/science/84/8426sci1.html">profiled<br />
Daly in 2006</a>, before I joined the staff.</p>
<p>The name of the toxin perhaps should have rung a bell for me back in 2000. The <a rel="nofollow" target="_blank" href="http://pubs.acs.org/doi/pdf/10.1021/ja981258g">first total synthesis</a> of the molecule had been published in 1998. It was by my undergraduate adviser, Y<a rel="nofollow" target="_blank" href="http://www.chem.harvard.edu/research/faculty/yoshito_kishi.php">oshito<br />
Kishi</a>. One of the coauthors had been a labmate of mine. I wish I could remember whether he’d been working on it during my years in the lab, in ‘93 and ‘94.</p>
<div id="crp_related"><h3>Related Posts:</h3><ul><li><a rel="nofollow" target="_blank" href="http://cenblog.org/2009/09/whats-in-your-fridge/" class="crp_title">What&#39;s In Your Fridge?</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/the-safety-zone/2012/05/water-and-oxygen-my-favorite-toxic-chemicals/" class="crp_title">Water and oxygen, my favorite toxic chemicals</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/the-haystack/2012/05/tetrodotoxin-why-toxic-is-complicated/" class="crp_title">Tetrodotoxin: Why Toxic Is Complicated</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/newscripts/2011/06/amusing-news-aliquots-4/" class="crp_title">Amusing News Aliquots</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/the-safety-zone/2011/09/your-favorite-chemical-reaction/" class="crp_title">Your favorite chemical reaction?</a></li></ul></div><div class="feedflare">
<a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=wQMTDDWqRRc:9xmbqKPbRyg:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=wQMTDDWqRRc:9xmbqKPbRyg:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=wQMTDDWqRRc:9xmbqKPbRyg:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=wQMTDDWqRRc:9xmbqKPbRyg:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=wQMTDDWqRRc:9xmbqKPbRyg:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=wQMTDDWqRRc:9xmbqKPbRyg:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"></img></a>
</div><img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/wQMTDDWqRRc" height="1" width="1"/>]]></content:encoded>
      <feedburner:origLink>http://cenblog.org/newscripts/2012/05/a-toxic-tale-of-serendipity/</feedburner:origLink></item>
      <item>
         <title>Worst And/Or Craziest Misconceptions</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/JlcPL7KvYq4/worst_andor_craziest_misconceptions.php</link>
         <description>&lt;p&gt;You run into a lot of scientific and medical misconceptions (particularly when you have a blog with a working e-mail address plastered on the front page of it!) There are plenty of harmless ones that are easy to correct, and at the other end of the scale there are major &lt;i&gt;weltanschauung&lt;/i&gt; problems (like the "drug companies don't want to find a cure for cancer because it would put them out of business" line). Those involve what Kingsley Amis called "permanent tendencies of the heart and mind", and I'm not sure if they can be fixed at all.&lt;/p&gt;

&lt;p&gt;I got to thinking about this subject again after seeing &lt;a rel="nofollow" target="_blank" href="http://www.medpagetoday.com/MeetingCoverage/AUA/32857"&gt;this item&lt;/a&gt;, which is pointing out to physicians that a meaningful number of their patients may well opt out of surgery for cancer because they believe that cancer spreads when exposed to air. This turns out to be a &lt;a rel="nofollow" target="_blank" href="http://www.caring.com/questions/does-surgery-make-cancer-spread-faster"&gt;common&lt;/a&gt; enough belief that it's &lt;a rel="nofollow" target="_blank" href="http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/Surgery/surgery-surgery-and-cancer-spread"&gt;addressed&lt;/a&gt; on many medical sites. It's not one that I'd heard before, and I thought I'd heard quite a few of these.&lt;/p&gt;

&lt;p&gt;So, in the spirit of discussions like &lt;a rel="nofollow" target="_blank" href="http://www.reddit.com/r/AskReddit/comments/u27lv/today_my_girlfriend_told_me_that_she_would_never/"&gt;this one&lt;/a&gt;, I'll toss out these questions: what's the farthest-from-reality misconception about medical/pharma topics you've encountered? And what widespread one do you think does the most harm? (Warning about that link: it goes to a hugely long thread, which will soak up your time as you continue running into yet-more-ridiculous beliefs that people have expressed).&lt;/p&gt;

&lt;p&gt;My own candidates: the weirdest one I've encountered might be the person who still believed in spontaneous generation (that old bread just sort of "turned into" living mold, etc.). And the most harmful one, from a drug research perspective, might well be the constellation of "the government does all drug research" beliefs, or the one mentioned above, the "drug companies don't want to cure X" one, which shades into the  "drug companies have a cure for X but they don't want to release it" belief.&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/InThePipeline/~4/oybiLcB8UIw" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=JlcPL7KvYq4:oybiLcB8UIw:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=JlcPL7KvYq4:oybiLcB8UIw:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=JlcPL7KvYq4:oybiLcB8UIw:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=JlcPL7KvYq4:oybiLcB8UIw:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=JlcPL7KvYq4:oybiLcB8UIw:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=JlcPL7KvYq4:oybiLcB8UIw:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/JlcPL7KvYq4" height="1" width="1"/&gt;</description>
         <guid isPermaLink="false">http://pipeline.corante.com/archives/2012/05/25/worst_andor_craziest_misconceptions.php</guid>
         <pubDate>Fri, 25 May 2012 12:35:40 +0000</pubDate>
         <category>General Scientific News</category>
      <feedburner:origLink>http://feedproxy.google.com/~r/InThePipeline/~3/oybiLcB8UIw/worst_andor_craziest_misconceptions.php</feedburner:origLink></item>
      <item>
         <title>Water and oxygen, my favorite toxic chemicals</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/eOBHm3daETo/</link>
         <description>(Russ&amp;#8217;s post on osmium earlier this week and mine today are both for the &amp;#8220;Our favorite toxic chemicals&amp;#8221; carnival hosted by Sciencegeist. Go see the collected posts from Monday, Tuesday, and Wednesday. On Twitter, watch #ToxicCarnival.) In 2005, a California State University, Chico, student died after being forced to drink gallons of water during a [...]</description>
         <guid isPermaLink="false">http://2.2885</guid>
         <pubDate>Thu, 24 May 2012 21:48:48 +0000</pubDate>
         <content:encoded><![CDATA[<p><em>(<a rel="nofollow" target="_blank" href="http://cenblog.org/the-safety-zone/2012/05/my-favorite-toxic-chemical-is%E2%80%A6-osmium-and-its-tetroxide/">Russ&#8217;s post on osmium</a> earlier this week and mine today are both for the <a rel="nofollow" target="_blank" href="http://sciencegeist.net/our-favorite-toxic-chemicals/">&#8220;Our favorite toxic chemicals&#8221;</a> carnival hosted by Sciencegeist. Go see the collected posts from <a rel="nofollow" target="_blank" href="http://sciencegeist.net/toxic-carnival-day-one/">Monday</a>, <a rel="nofollow" target="_blank" href="http://sciencegeist.net/toxic-carnival-day-two/">Tuesday</a>, and <a rel="nofollow" target="_blank" href="http://sciencegeist.net/toxic-carnival-day-three/">Wednesday</a>. On Twitter, watch <a rel="nofollow" target="_blank" href="https://twitter.com/#!/search/%23Toxiccarnival">#ToxicCarnival</a>.)</em></p>
<div id="attachment_2891" class="wp-caption alignright" style="width:310px;"><a rel="nofollow" target="_blank" href="http://cenblog.org/the-safety-zone/files/2012/05/GlassOfWater-shutterstock-stocknadia.jpg" class="thickbox no_icon" title=""><img class="size-medium wp-image-2891" src="http://cenblog.org/the-safety-zone/files/2012/05/GlassOfWater-shutterstock-stocknadia-300x199.jpg" alt="" width="300" height="199"/></a><p class="wp-caption-text">Credit: stocknadia/Shutterstock</p></div>
<p>In 2005, a California State University, Chico, student died after being <a rel="nofollow" target="_blank" href="http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2005/03/04/MNGK9BKG681.DTL">forced to drink gallons of water during a fraternity hazing ritual</a>. <a rel="nofollow">Four of his fraternity brothers pleaded guilty</a> to charges ranging from involuntary manslaughter to hazing. In 2007, a woman participating in a radio contest to win a Nintendo Wii died after <a rel="nofollow" target="_blank" href="http://articles.latimes.com/2007/jan/18/local/me-radio18">drinking nearly 2 gallons of water without urinating</a>. <a rel="nofollow" target="_blank" href="http://latimesblogs.latimes.com/lanow/2009/10/jury-awards-16-million-in-radio-prank-that-left-sacramentoarea-woman-dead-.html">A jury later awarded $16 million to her family</a>.</p>
<p>Water, H<sub>2</sub>O. Oxygen, O<sub>2</sub>. Without either one, we die. But also: With too much H<sub>2</sub>O, we die. With too much O<sub>2</sub>, we die.  The dose makes the poison.</p>
<p>H<sub>2</sub>O is essentially the solvent in which all cellular substances are dissolved. Overall, <a rel="nofollow" target="_blank" href="http://ga.water.usgs.gov/edu/propertyyou.html">the human body is about 60% H<sub>2</sub>O</a>, although the amount varies depending on the body part: bone is 22%, brain is 70%, and blood is 83%. H<sub>2</sub>O is polar, with the oxygen carrying a slight negative and the hydrogens carrying a slight positive charge. That means that H<sub>2</sub>O tends to form strong interactions with other polar molecules but rebuff nonpolar ones, which is why dispersed oil droplets will gather together in a cup of H<sub>2</sub>O. At the cellular level, those polar and nonpolar interactions play an important role in things such as membrane formation, protein folding, and protein-protein or protein-substrate binding.</p>
<p>But as the news reports above demonstrate, H<sub>2</sub>O can also kill, and not just by drowning. Drink more H<sub>2</sub>O than your kidneys can handle and the fluid builds up in your blood, diluting the sodium concentration&#8211;a condition called <a rel="nofollow" target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001431/">hyponatremia</a>. <a rel="nofollow" target="_blank" href="http://en.wikipedia.org/wiki/Osmosis">H<sub>2</sub>O then moves into cells to equalize</a> the sodium concentration between the two environments. The influx of H<sub>2</sub>O causes cells to swell. Some parts of your body have room for that, but your brain does not. &#8220;Rapid and severe hyponatremia causes entry of water into brain cells leading to brain swelling, which manifests as seizures, coma, respiratory arrest, brain stem herniation and death,&#8221; M. Amin Arnaout, chief of nephrology at Massachusetts General Hospital and Harvard Medical School, <a rel="nofollow" target="_blank" href="http://www.scientificamerican.com/article.cfm?id=strange-but-true-drinking-too-much-water-can-kill">told Scientific American</a>.</p>
<p>For its part, O<sub>2</sub> is a key player in cellular energy cycles. We breathe in O<sub>2</sub>, which red blood cells deliver throughout our bodies. <a rel="nofollow" target="_blank" href="http://en.wikipedia.org/wiki/Mitochondrion">Mitochondria</a> in other cells turn that O<sub>2</sub>, sugar, and adenosine diphosphate into H<sub>2</sub>O, CO<sub>2</sub>, and <a rel="nofollow" target="_blank" href="http://en.wikipedia.org/wiki/Adenosine_triphosphate">adenosine triphosphate</a> (ATP). ATP then serves as the energy source for a multitude of other cellular activities involved in being alive. One molecule of glucose produces 36-38 molecules of ATP.</p>
<p>But human bodies evolved to breathe in O<sub>2</sub> as about 20% of air. Breathing higher concentrations can lead to <a rel="nofollow" target="_blank" href="http://en.wikipedia.org/wiki/Oxygen_toxicity">hyperoxia</a>, or higher-than-normal concentrations of oxygen in body tissues. Increasing the percentage of oxygen to about 50% can cause damage to the lungs and eyes. Increasing the pressure as well, such as in <a rel="nofollow" target="_blank" href="http://www.mayoclinic.com/health/hyperbaric-oxygen-therapy/MY00829">hyperbaric chambers</a>, can be toxic to the central nervous system.</p>
<p>Water and oxygen. H<sub>2</sub>O and O<sub>2</sub>. Necessary for life. But there can, in fact, be too much of a good thing.</p>
<div id="crp_related"><h3>Related Posts:</h3><ul><li><a rel="nofollow" target="_blank" href="http://cenblog.org/the-safety-zone/2012/05/friday-chemical-safety-round-up-42/" class="crp_title">Friday chemical safety round-up</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/cleantech-chemistry/2012/05/our-favorite-toxic-chemical-nitrate/" class="crp_title">Our Favorite Toxic Chemical: Nitrate</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/the-safety-zone/2012/05/my-favorite-toxic-chemical-is%e2%80%a6-osmium-and-its-tetroxide/" class="crp_title">My favorite toxic chemical is: Osmium (and its tetroxide)</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/the-haystack/2011/08/sweet-science-glucose-regulates-stem-cells-cancer/" class="crp_title">Sweet Science: Glucose Regulates Stem Cells, Cancer</a></li><li><a rel="nofollow" target="_blank" href="http://cenblog.org/iyc-2011/2011/09/its-chemistry-carnival-time/" class="crp_title">It&#8217;s Chemistry Carnival Time!</a></li></ul></div><div class="feedflare">
<a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=eOBHm3daETo:4dhD5r2q7q0:yIl2AUoC8zA"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=eOBHm3daETo:4dhD5r2q7q0:F7zBnMyn0Lo"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=eOBHm3daETo:4dhD5r2q7q0:F7zBnMyn0Lo" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=eOBHm3daETo:4dhD5r2q7q0:V_sGLiPBpWU"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=eOBHm3daETo:4dhD5r2q7q0:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=eOBHm3daETo:4dhD5r2q7q0:I9og5sOYxJI"><img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"></img></a>
</div><img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/eOBHm3daETo" height="1" width="1"/>]]></content:encoded>
      <feedburner:origLink>http://cenblog.org/the-safety-zone/2012/05/water-and-oxygen-my-favorite-toxic-chemicals/</feedburner:origLink></item>
      <item>
         <title>An Oral Insulin Pill?</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/vHPHvPj6hRc/an_oral_insulin_pill.php</link>
         <description>&lt;p&gt;Bloomberg &lt;a rel="nofollow" target="_blank" href="http://www.bloomberg.com/news/2012-05-22/novo-s-insulin-pill-quest-is-holy-grail-for-novo-health.html"&gt;has an article&lt;/a&gt; on Novo Nordisk and their huge ongoing effort to come up with an orally available form of insulin. That's been a dream for a long time now, but it's always been thought to be very close to impossible. The reasons for this are &lt;a rel="nofollow" target="_blank" href="http://pipeline.corante.com/archives/2002/05/22/now_is_the_peptide_of_our_discontent.php"&gt;well known&lt;/a&gt;: your gut will treat a big protein like insulin pretty much like it treats a hamburger. It'll get digested, chopped into its constituent amino acids, and absorbed as non-medicinally-active bits which are used as raw material once inside the body. That's what digestion is. The gut wall specifically guards against letting large biomolecules through intact.&lt;/p&gt;

&lt;p&gt;So you're up against a lot of defenses when you try to make something like oral insulin. Modifying the protein itself to make it more permeable and stable will be a big part of it, and formulating the pill to escape the worst of the gut environments will be another. Even then, you have to wonder about patient-to-patient variability in digestion, intestinal flora, and so on. The dosing is probably going to have to be pretty strict with respect to meals (and the content of those meals).&lt;/p&gt;

&lt;p&gt;But insulin dosing is always going to be strict, because there's a narrow window to work in. That's one of the factors that's helped to sink so many other alternative-dosing schemes for it, &lt;a rel="nofollow" target="_blank" href="http://pipeline.corante.com/archives/2007/10/22/surveying_the_exubera_crater.php"&gt;most famously&lt;/a&gt; Pfizer's Exubera. The body's response to insulin in brittle in the extreme. If you take twice as much antihistamine as you should, you may feel funny. If you take twice as much insulin as you should, you're going to be on the floor, and you may stay there.&lt;/p&gt;

&lt;p&gt;So I salute Novo Nordisk for trying this. The rewards will be huge if they get it to work, but it's a long way from working just yet.&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/InThePipeline/~4/FnbOMroki6w" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=vHPHvPj6hRc:FnbOMroki6w:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=vHPHvPj6hRc:FnbOMroki6w:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=vHPHvPj6hRc:FnbOMroki6w:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=vHPHvPj6hRc:FnbOMroki6w:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=vHPHvPj6hRc:FnbOMroki6w:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=vHPHvPj6hRc:FnbOMroki6w:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/vHPHvPj6hRc" height="1" width="1"/&gt;</description>
         <guid isPermaLink="false">http://pipeline.corante.com/archives/2012/05/24/an_oral_insulin_pill.php</guid>
         <pubDate>Thu, 24 May 2012 12:11:00 +0000</pubDate>
         <category>Diabetes and Obesity</category>
      <feedburner:origLink>http://feedproxy.google.com/~r/InThePipeline/~3/FnbOMroki6w/an_oral_insulin_pill.php</feedburner:origLink></item>
      <item>
         <title>Publishing Without Consent</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/-nQd6RPfIIA/publishing_without_consent.php</link>
         <description>&lt;p&gt;&lt;a rel="nofollow" target="_blank" href="http://www.biotechniques.com/news/biotechniquesNews/biotechniques-330913.html?utm_source=BioTechniques+Newsletters+%2526+e-Alerts&amp;utm_campaign=2b6ed86255-Daily&amp;utm_medium=email"&gt;Here's a note&lt;/a&gt; on an ugly situation: when a post-doc publishes a paper without the permission of the principal investigator. Now, this is a fairly rare situation, but still not as rare as you might imagine - the article itself has several citations, and it quotes a journal editor who's seen it happen a number of times.&lt;/p&gt;

&lt;p&gt;In most of these cases, there seems to be a more fundamental confusion about ownership of data, with publishing as the sequel. People leave a research group with their piles of results, and decide that since it's theirs, that it's time to get it out into the literature with their name on it. But as the article points out, if work is done under NIH funding, then the results belong to the institution, and the grantee/PI is the person who decides when and where things are published. You may, as a grad student or post-doc, feel that the data you worked so hard to generate are rightfully yours, but most of the time that's just not the case.&lt;/p&gt;

&lt;p&gt;In industry we have our own disputes, but this isn't one of them. There's rarely any argument about ownership of data: that's all company property, and you sign documents when you're hired that explicitly spell that out. And publication is rarely as bitter a business as it is in academia (where it's the coin of the realm). We argue about whether a particular project is advanced enough (or dead enough, more likely) to be written up for a journal, but these are secondary questions.&lt;/p&gt;

&lt;p&gt;Who gets on the patent is a slightly bigger question, but it's not like you get a cut of the profits based on whether your name is on the list. That's as opposed to Germany, where that's exactly what happens, and I've often wondered if we should try that here. That system leads to some elbow-throwing when it comes to inventorship on a hot project, but it also leads to everyone having a clear idea of the legal requirements to be an inventor. Ownership is, naturally, not in dispute at all. Every invention realized at the company is company property, too (those same documents take care of that back when you're hired on).&lt;/p&gt;

&lt;p&gt;So while rogue academic publishing is a known phenomenon, rogue industrial patenting isn't. Well, as far as I know it isn't - anyone have an example of someone who tried to get away with it?&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/InThePipeline/~4/HRhH5bHnjtc" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=-nQd6RPfIIA:HRhH5bHnjtc:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=-nQd6RPfIIA:HRhH5bHnjtc:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=-nQd6RPfIIA:HRhH5bHnjtc:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=-nQd6RPfIIA:HRhH5bHnjtc:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=-nQd6RPfIIA:HRhH5bHnjtc:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=-nQd6RPfIIA:HRhH5bHnjtc:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/-nQd6RPfIIA" height="1" width="1"/&gt;</description>
         <guid isPermaLink="false">http://pipeline.corante.com/archives/2012/05/24/publishing_without_consent.php</guid>
         <pubDate>Thu, 24 May 2012 11:15:16 +0000</pubDate>
         <category>The Scientific Literature</category>
      <feedburner:origLink>http://feedproxy.google.com/~r/InThePipeline/~3/HRhH5bHnjtc/publishing_without_consent.php</feedburner:origLink></item>
      <item>
         <title>How Come?</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/y52wb5g-NuM/how_come.php</link>
         <description>&lt;p&gt;I'm baffled by &lt;a rel="nofollow" target="_blank" href="http://pubs.acs.org/doi/abs/10.1021/jm300427m"&gt;this abstract&lt;/a&gt;. Why would you go to the trouble of putting an unusual group (a ferrocene) on a molecule, and then show that putting it on seems to do little or nothing to the properties and activity of the parent compound? "We put a ferrocene on and it didn't kill the molecule" doesn't seem to be enough grounds for a full &lt;i&gt;J. Med. Chem.&lt;/i&gt; paper. Does it?&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/InThePipeline/~4/D5doAuI9d58" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=y52wb5g-NuM:D5doAuI9d58:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=y52wb5g-NuM:D5doAuI9d58:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=y52wb5g-NuM:D5doAuI9d58:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=y52wb5g-NuM:D5doAuI9d58:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=y52wb5g-NuM:D5doAuI9d58:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=y52wb5g-NuM:D5doAuI9d58:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/y52wb5g-NuM" height="1" width="1"/&gt;</description>
         <guid isPermaLink="false">http://pipeline.corante.com/archives/2012/05/23/how_come.php</guid>
         <pubDate>Wed, 23 May 2012 16:16:56 +0000</pubDate>
         <category>The Scientific Literature</category>
      <feedburner:origLink>http://feedproxy.google.com/~r/InThePipeline/~3/D5doAuI9d58/how_come.php</feedburner:origLink></item>
      <item>
         <title>Drug Discovery on Radio 4</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/TL9Ui2IXtPU/drug_discovery_on_radio_4.php</link>
         <description>&lt;p&gt;Several readers sent along a link to &lt;a rel="nofollow" target="_blank" href="http://www.bbc.co.uk/iplayer/episode/b01hxh76/The_End_of_Drug_Discovery/"&gt;this Radio 4 program&lt;/a&gt; ("The End of Drug Disocvery") from the &lt;a rel="nofollow" target="_blank" href=" http://www.bbc.co.uk/programmes/b01hxh76"&gt;BBC&lt;/a&gt; on drug discovery. From what I've heard, it's a very good overview of the current state of the field for people outside it, and gets across just how difficult it's been to find good drug candidates.&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/InThePipeline/~4/O7HRXA31QMo" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=TL9Ui2IXtPU:O7HRXA31QMo:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=TL9Ui2IXtPU:O7HRXA31QMo:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=TL9Ui2IXtPU:O7HRXA31QMo:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=TL9Ui2IXtPU:O7HRXA31QMo:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=TL9Ui2IXtPU:O7HRXA31QMo:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=TL9Ui2IXtPU:O7HRXA31QMo:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/TL9Ui2IXtPU" height="1" width="1"/&gt;</description>
         <guid isPermaLink="false">http://pipeline.corante.com/archives/2012/05/23/drug_discovery_on_radio_4.php</guid>
         <pubDate>Wed, 23 May 2012 11:34:09 +0000</pubDate>
         <category>Press Coverage</category>
      <feedburner:origLink>http://feedproxy.google.com/~r/InThePipeline/~3/O7HRXA31QMo/drug_discovery_on_radio_4.php</feedburner:origLink></item>
      <item>
         <title>Another Vote Against Rhodanines</title>
         <link>http://feedproxy.google.com/~r/DrugDiscoveryBlogs/~3/i47BlRmP07E/another_vote_against_rhodanines.php</link>
         <description>&lt;p&gt;For those of you who'd had to explain to colleagues (in biology or chemistry) why you're &lt;a rel="nofollow" target="_blank" href="http://pipeline.corante.com/archives/2010/02/19/two_for_one_sale.php"&gt;not enthusiastic&lt;/a&gt; about the rhodanine compounds that came out of your high-throughput screening effort, there's now &lt;a rel="nofollow" target="_blank" href="http://informahealthcare.com/doi/abs/10.1517/17460441.2012.688743"&gt;another paper&lt;/a&gt; to point them to.&lt;/p&gt;

&lt;p&gt;&lt;i&gt;&lt;blockquote&gt;The biological activity of compounds possessing a rhodanine moiety should be considered very critically despite the convincing data obtained in biological assays. In addition to the lack of selectivity, unusual structure–activity relationship profiles and safety and specificity problems mean that rhodanines are generally not optimizable.&lt;/i&gt;&lt;/blockquote&gt;&lt;/p&gt;

&lt;p&gt;That's well put, I think, although this has been a subject of &lt;a rel="nofollow" target="_blank" href="http://pipeline.corante.com/archives/2011/12/06/riding_to_the_rescue_of_rhodanines.php"&gt;debate&lt;/a&gt;. I would apply the same language to the other "&lt;a rel="nofollow" target="_blank" href="http://pipeline.corante.com/archives/2010/02/08/polluting_the_literature_with_pains.php"&gt;PAINS&lt;/a&gt;" mentioned in the &lt;a rel="nofollow" target="_blank" href="http://pubs.acs.org/doi/abs/10.1021/jm901137j"&gt;Baell and Holloway paper&lt;/a&gt;, which brought together a number of motifs that have set off alarm bells over the years. These structures are guilty until proven innocent. If you have a high-value target and feel that it's worth the time and trouble to prove them so, that may well be the right decision. But if you have something else to advance, you're better off doing so. As I've said here before, &lt;i&gt;ars longa, pecunia brevis&lt;/i&gt;.&lt;/p&gt;&lt;img src="http://feeds.feedburner.com/~r/InThePipeline/~4/Pao0K_VLAM4" height="1" width="1"/&gt;&lt;div class="feedflare"&gt;
&lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=i47BlRmP07E:Pao0K_VLAM4:yIl2AUoC8zA"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=yIl2AUoC8zA" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=i47BlRmP07E:Pao0K_VLAM4:F7zBnMyn0Lo"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=i47BlRmP07E:Pao0K_VLAM4:F7zBnMyn0Lo" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=i47BlRmP07E:Pao0K_VLAM4:V_sGLiPBpWU"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?i=i47BlRmP07E:Pao0K_VLAM4:V_sGLiPBpWU" border="0"&gt;&lt;/img&gt;&lt;/a&gt; &lt;a href="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?a=i47BlRmP07E:Pao0K_VLAM4:I9og5sOYxJI"&gt;&lt;img src="http://feeds.feedburner.com/~ff/DrugDiscoveryBlogs?d=I9og5sOYxJI" border="0"&gt;&lt;/img&gt;&lt;/a&gt;
&lt;/div&gt;&lt;img src="http://feeds.feedburner.com/~r/DrugDiscoveryBlogs/~4/i47BlRmP07E" height="1" width="1"/&gt;</description>
         <guid isPermaLink="false">http://pipeline.corante.com/archives/2012/05/23/another_vote_against_rhodanines.php</guid>
         <pubDate>Wed, 23 May 2012 11:17:02 +0000</pubDate>
         <category>Drug Assays</category>
      <feedburner:origLink>http://feedproxy.google.com/~r/InThePipeline/~3/Pao0K_VLAM4/another_vote_against_rhodanines.php</feedburner:origLink></item>
   </channel>
</rss><!-- fe3.yql.bf1.yahoo.com compressed/chunked Sun May 27 17:55:11 UTC 2012 -->

